Elicio Therapeutics announces preclinical data on TCR-T therapy

Elicio Therapeutics announced the publication of promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research, AACR. These preclinical data demonstrate that Elicio’s proprietary “AMP” lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell therapies, TCR-T cells, enhancing anti-tumor function and eradicating solid tumors. Robert Connelly, Chief Executive Officer at Elicio Therapeutics, added, “This study adds to our growing body of preclinical and clinical evidence demonstrating the importance of the lymph nodes and the robust efficacy that our AMP immunotherapy strategy can potentially achieve for patients with solid tumors, both as a monotherapy and in combination with other strategies. The AMP platform provides attractive potential for broad and rapid application to clinical and developmental TCR-T cell programs. We look forward to finding the right partner to advance this promising combination into the clinic for patients with solid tumors.”